ST. HELIER, Jersey–(Company WIRE)–
Novocure (NASDAQ: NVCR) introduced these days that it will report monetary effects for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. economical markets open. Novocure’s administration will host a convention get in touch with and webcast to explore its monetary benefits for the 3 and nine months finished September 30, 2020, at 8 a.m. EDT on Thursday, October 29, 2020. Analysts and investors can participate in the meeting get in touch with by dialing 855-442-6895 for domestic callers and 509-960-9037 for global callers, utilizing the convention ID 5453859.

The webcast and earnings slides offered during the webcast can be accessed reside from the Investor Relations web site of Novocure’s internet site,, and will be offered for at the very least 14 times adhering to the phone. Novocure has used, and intends to carry on to use, its investor relations web site, as a implies of disclosing materials non-community details and for complying with its disclosure obligations underneath Regulation FD.

About Novocure

Novocure is a world-wide oncology enterprise doing work to extend survival in some of the most intense sorts of most cancers by the enhancement and commercialization of its revolutionary therapy, Tumor Managing Fields. Novocure’s commercialized merchandise are authorised in specified international locations for the treatment of adult people with glioblastoma and in the U.S. for the therapy of adult clients with malignant pleural mesothelioma. Novocure has ongoing or concluded medical trials investigating Tumor Treating Fields in mind metastases, non-smaller cell lung most cancers, pancreatic cancer, ovarian cancer, liver most cancers, gastric most cancers and glioblastoma.

Headquartered in Jersey, Novocure has U.S. functions in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York Town. In addition, the corporation has places of work in Germany, Switzerland, Japan and Israel. For further information about the corporation, you should go to or adhere to us at

Ahead-Looking Statements

In addition to historical specifics or statements of latest issue, this push launch could comprise ahead-looking statements. Ahead-wanting statements offer Novocure’s present-day anticipations or forecasts of foreseeable future functions. These might contain statements pertaining to expected scientific development on its research programs, clinical trial development, advancement of prospective products, interpretation of medical results, potential customers for regulatory approval, producing growth and abilities, sector prospective clients for its products, protection, collections from 3rd-occasion payers and other statements regarding issues that are not historical points. You may possibly detect some of these forward-searching statements by the use of words in the statements this kind of as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and phrases and conditions of equivalent which means. Novocure’s functionality and economic outcomes could differ materially from individuals reflected in these ahead-wanting statements owing to basic money, financial, regulatory and political ailments as nicely as difficulties arising from the COVID-19 pandemic and other more unique hazards and uncertainties facing Novocure these types of as individuals established forth in its Annual Report on Type 10-K filed on February 27, 2020 and its Quarterly Report on Type 10-Q filed on April 30, 2020 with the U.S. Securities and Exchange Fee. Supplied these dangers and uncertainties, any or all of these forward-searching statements might show to be incorrect. As a result, you should really not rely on any such factors or ahead-hunting statements. In addition, Novocure does not intend to update publicly any ahead-searching statement, except as demanded by legislation. Any ahead-looking statements herein talk only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

See supply model on

Gabrielle Fernandes
[email protected]

Jaclyn Stahl
[email protected]

Supply: Novocure